Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05833230
Other study ID # 2000034321
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 1, 2023
Est. completion date January 30, 2025

Study information

Verified date June 2024
Source Yale University
Contact Stephanie Wemm, PhD
Phone 203-737-3436
Email stephanie.wemm@yale.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research project proposes a novel approach to elucidate the biological adaptations associated with heavy cannabis use and to assess whether such adaptations are predictive of higher cannabis craving in response to both cannabis cues and stressors.


Description:

As more states in the US have legalized recreational cannabis use, the number of individuals who use cannabis has also increased. Individuals are also using cannabis more frequently and in larger amounts as it has become more available and less challenging to purchase. These statistics are alarming because heavy use of cannabis has been linked to several societal and public health concerns, such as poorer mental health outcomes, higher rates of unemployment, and poorer life satisfaction. Many of these associations are associated with increased burden and stress; however, cannabis may alter how individuals cope biologically, such as the stress hormone cortisol, and psychologically with these stressors. For example, heavy use of alcohol and other drugs, such as cocaine or nicotine, change overall cortisol levels and how cortisol is released in response to stress. In laboratory studies, healthy individuals show a peak in cortisol following a stressor, whereas individuals who use alcohol and substances heavily have a less robust response. However, it is not known if this phenomenon occurs in individuals who use cannabis heavily in real-world stressful situations. Heavier use of alcohol or drugs is associated with wanting or craving drugs or alcohol more when in stressful situations. In this proposal, the team will use smartphone-delivered surveys combined with regular saliva sampling to examine the associations between psychological and biological stress responses and cannabis use. Individuals who use cannabis at least once weekly will be recruited to complete two weeks of smartphone surveys. The participants will also provide regular saliva samples and wear a heart rate monitor on three consecutive days within those two weeks. These saliva samples will be analyzed for the hormone cortisol and salivary alpha amylase. The team will examine if self-reported cannabis use predicts how an individual responds, both biological and psychological, to a stressor when they encounter it their daily life. The team will also investigate if individuals who use more cannabis are more likely to want to use cannabis when they encounter daily life stress. Results from this study can help us develop treatments that help individuals who use cannabis heavily better cope with stress.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date January 30, 2025
Est. primary completion date January 30, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Cannabis-using men and women who: - have a past-year pattern of 1 or more cannabis use episodes per week - do not meet criteria for any other substance use disorders other than mild Cannabis and Alcohol Use Disorder - are at least 18 years old - are fluent in English - can provide negative alcohol breathalyzer and only positive for cannabis at all visits. - can provide written informed consent. Exclusion Criteria: Individuals will be excluded if they: - meeting current or past for major psychiatric disorders, other than depression or anxiety disorder; - meeting criteria for a current Substance Use Disorder other than mild Cannabis Use Disorder and Alcohol Use Disorder; - any significant current medical conditions requiring medication, including neurological, renal, thyroid, cardiovascular, liver, endocrine, or immune conditions - current use of medications that interfere with hypothalamic-pituitary-adrenal axis response - women who are pregnant, lactating, peri-/post-menopausal, or with hysterectomies - current use of psychotropic drugs other than antidepressants.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Intensive Day Monitoring
During intake, a research assistant will demonstrate how to place the Heart Rate Variability monitor and provide instructions on completing the saliva samples at home. Participants will wear the Heart Rate Variability monitor for three consecutive, randomly selected days twice (72 hours each). Participants will be provided with six saliva sample collection tubes per day with explicit directions on when the saliva sampling should occur (hours since waking: +0, +1, +2, +4, +6, +10 hours, and before going to sleep). Participants will also complete a subjective report using similar questions included in the survey prompts at the same scheduled time as the saliva sample. All participants will complete a total of 6 such days during the study.

Locations

Country Name City State
United States Yale Stress Center New Haven Connecticut

Sponsors (2)

Lead Sponsor Collaborator
Yale University Robert E. Leet and Clara Guthrie Patterson Trust Mentored Research Award

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Averaged cortisol response to stress and cannabis cues in the real world Saliva samples for cortisol levels will be collected throughout the day on a randomly selected three-day period during week 1 of the study. The data will be averaged on all three days and not treated as separate time points. 3 days in Week 1
Primary Ratings of subjective craving in the real world Participants will report using ecological momentary assessment (EMA) their current levels of craving. These reports will be generated in three different ways: at 8 am and 8 pm at night, at four random times during waking hours, and while drinking alcohol. Craving will be assessed using a 100-point visual analog scale (VAS) in which 0="Not at all" and 100="Extremely High." 48 days
Primary Ratings of subjective subjective stress in the real world Participants will report using ecological momentary assessment (EMA) their current levels of stress. These reports will be generated in three different ways: at 8 am and 8 pm at night, at four random times during waking hours, and while drinking alcohol. Stress will be assessed using a 100-point visual analog scale (VAS) in which 0="Not at all" and 100="Extremely High." 48 days
Secondary Self-reported cannabis use Participants will report how recently they've used cannabis. Self-reports of stress, stress biology, and craving will be used to predict next-moment self-reported cannabis use (use since last assessment = 1, no use since last assessment = 0) from the smartphone assessments. 48 days
See also
  Status Clinical Trial Phase
Completed NCT03253926 - Effect of Lorcaserin on Cannabis Withdrawal and Self-administration Phase 1/Phase 2
Completed NCT04060602 - Personalized Feedback Intervention to Reduce Risky Cannabis Use. N/A
Completed NCT01212081 - Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality
Recruiting NCT04988490 - Quantification of Cannabinoids and Comparison to Post-Surgical Pain Medication Requirements and Surgical Outcomes
Recruiting NCT05188404 - Aging and Marijuana: Benefits, Effects, and Risks
Completed NCT03662737 - VRT as a Biomarker of Cerebellar Dysfunction in Chronic Cannabis Use
Not yet recruiting NCT05999383 - Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration Phase 2
Terminated NCT04436055 - Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
Active, not recruiting NCT04374773 - Effects of Pregnancy-associated Hormones on THC Metabolism in Women Phase 4
Completed NCT04316741 - Brief Intervention Combined With Health Coaching Via Social Media for Cannabis Use N/A
Recruiting NCT05396638 - Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder N/A
Recruiting NCT05309226 - Cannabis Use in Pregnancy and Downstream Effects on Maternal and Infant Health
Recruiting NCT03859089 - Cannabis for Opioid Substitution Trial
Recruiting NCT05849636 - Alerta Cannabis: Evaluation of Web-based Tailored Intervention N/A
Enrolling by invitation NCT05521321 - Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit N/A
Recruiting NCT05119244 - Environment and Lung Cancer N/A
Recruiting NCT04841655 - Tobacco Cessation Among Smokers Under Alcohol and/or Cannabis Treatment
Terminated NCT04100590 - Eye Tracking as a Biomarker of Cannabis Effects Phase 2
Completed NCT05167097 - Mindsets and the Effectiveness of a Brief Intervention - Replication N/A
Recruiting NCT04114903 - Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity